It is important to keep in mind, however, that some of these substances may have pharmacological limitations, including the mechanism of drug action, administration route, tolerability, side effects, and proven efficacy, that should be considered before they could be approved for its use in this pathology
Medical Writing and Editorial Assistance The authors would like to thank Carsten Roepstorff, PhD, CR Pharma Consult, Copenhagen, Denmark for providing medical writing support, which was funded by Novo Nordisk
Key takeaway Both medicines can support significant weight loss, especially at the higher, weight-management doses (Wegovy for semaglutide and Zepbound for tirzepatide)
The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target
In therapeutic groups treated with GbE or LC (Fig